Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6601 AL 6615

The development of new therapeutics for Alzheimer's disease

Carter MD, Simms GA, Weaver DF.

Clin Pharmacol Ther. 2010 Oct;88(4):475-86. doi: 10.1038/clpt.2010.165. Epub 2010 Sep 1.

The role of tau kinases in Alzheimer's disease

Dolan PJ, Johnson GV.

Curr Opin Drug Discov Devel. 2010 Sep;13(5):595-603.

Alzheimer's disease: effects of β-amyloid on mitochondria

Tillement L, Lecanu L, Papadopoulos V.

Mitochondrion. 2011 Jan;11(1):13-21. doi: 10.1016/j.mito.2010.08.009. Epub 2010 Sep 15.

The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease

Farlow MR, Grossberg G, Gauthier S, Meng X, Olin JT.

Curr Med Res Opin. 2010 Oct;26(10):2441-7. doi: 10.1185/03007995.2010.513849.

Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative

Villard V, Espallergues J, Keller E, Vamvakides A, Maurice T.

J Psychopharmacol. 2011 Aug;25(8):1101-17. doi: 10.1177/0269881110379286. Epub 2010 Sep 9.

Docking of the alkaloid geissospermine into acetylcholinesterase: a natural scaffold targeting the treatment of Alzheimer's disease

Araújo JQ, Lima JA, Pinto Ada C, de Alencastro RB, Albuquerque MG.

J Mol Model. 2011 Jun;17(6):1401-12. doi: 10.1007/s00894-010-0841-2. Epub 2010 Sep 16.

Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models

Nagy B, Brennan A, Brandtmüller A, Thomas SK, Sullivan SD, Akehurst R.

Int J Geriatr Psychiatry. 2011 May;26(5):483-94. doi: 10.1002/gps.2551. Epub 2010 Sep 15.

B-vitamins and fatty acids in the prevention and treatment of Alzheimer's disease and dementia: a systematic review

Dangour AD, Whitehouse PJ, Rafferty K, Mitchell SA, Smith L, Hawkesworth S, Vellas B.

J Alzheimers Dis. 2010;22(1):205-24. doi: 10.3233/JAD-2010-090940.

Decline of human tactile angle discrimination in patients with mild cognitive impairment and Alzheimer's disease

Yang J, Ogasa T, Ohta Y, Abe K, Wu J.

J Alzheimers Dis. 2010;22(1):225-34. doi: 10.3233/JAD-2010-100723.

Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2, 3-dioxygenase activity in vitro

Yu CJ, Zheng MF, Kuang CX, Huang WD, Yang Q.

J Alzheimers Dis. 2010;22(1):257-66. doi: 10.3233/JAD-2010-100684.

Intranasal insulin as a therapeutic option in the treatment of cognitive impairments

Benedict C, Frey WH 2nd, Schiöth HB, Schultes B, Born J, Hallschmid M.

Exp Gerontol. 2011 Feb-Mar;46(2-3):112-5. doi: 10.1016/j.exger.2010.08.026. Epub 2010 Sep 16.

[Therapeutic strategies for Alzheimer disease based on endoplasmic reticulum stress]

Kudo T.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):163-8.

[Immunotherapy and Alzheimer's disease]

Arai H.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):173-6.

[Drug development for tauopathy and Alzheimer's disease]

Takashima A.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):177-80.

Cholinergic central system, Alzheimer's disease, and anesthetics liaison: a vicious circle?

Schifilliti D, Santamaria LB, Rosa G, Di Nino G, Mandal PK, Fodale V.

J Alzheimers Dis. 2010;22 Suppl 3:35-41. doi: 10.3233/JAD-2010-101317.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias